Report overview
This report contains market size and forecasts of Proto-Oncogene Drgu in global, including the following market information:
Global Proto-Oncogene Drgu Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Proto-Oncogene Drgu Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Proto-Oncogene Drgu companies in 2021 (%)
The global Proto-Oncogene Drgu market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Axitinib (Inlyta) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Proto-Oncogene Drgu include ARIAD Pharmaceuticals, AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, ChemGenex Pharmaceuticals, Dexa Medica, Eisai Pharmaceuticals, Exelixis and GlaxoSmithKline, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Proto-Oncogene Drgu manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Proto-Oncogene Drgu Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Proto-Oncogene Drgu Market Segment Percentages, by Type, 2021 (%)
Axitinib (Inlyta)
Ponatinib (Iclusig)
Imatinib (Gleevec)
Sunitinib (Sutent)
Pazopanib (Votrient)
Dabrafenib (Tafinlar)
Vandetanib (Caprelsa)
Vemurafenib (Zelboraf)
Cabozantinib (Cabometyx and Cometriq)
Sorafenib (Nexavar)
Global Proto-Oncogene Drgu Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Proto-Oncogene Drgu Market Segment Percentages, by Application, 2021 (%)
Clinic
Hospital
Others
Global Proto-Oncogene Drgu Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Proto-Oncogene Drgu Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Proto-Oncogene Drgu revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Proto-Oncogene Drgu revenues share in global market, 2021 (%)
Key companies Proto-Oncogene Drgu sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Proto-Oncogene Drgu sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
ARIAD Pharmaceuticals
AstraZeneca
Bayer Healthcare
Bristol-Myers Squibb
ChemGenex Pharmaceuticals
Dexa Medica
Eisai Pharmaceuticals
Exelixis
GlaxoSmithKline
Novartis
Onyx Pharmaceuticals
Plexxikon
Pfizer
